Analytical Data
-
Gene name
CDR1
- Application
-
Alternative Names
CDR34
-
Species
Human
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P51861
-
Expression Region
1-262aa
-
Molecular Weight
32.6
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDR1 (cytochrome c reductase 1) is a pivotal protein involved in various biological processes, including electron transport in mitochondria. Understanding CDR1's structure and function is crucial for elucidating its role in cellular respiration and energy metabolism. Recent research has highlighted its importance in various pathological conditions, including neurodegenerative diseases and metabolic disorders. Recombining CDR1 allows for the investigation of its functional properties and interactions with other cellular components. Moreover, the recombinant form of CDR1 can serve as a valuable tool in studying its enzymatic activity and potential as a therapeutic target. Advances in recombinant DNA technology have enabled the production of CDR1 in heterologous systems, facilitating large-scale purification and characterization. This progress opens the door for innovative approaches to drug design and development aimed at modulating CDR1 activity in disease states. Understanding the molecular mechanisms of CDR1 can ultimately contribute to the development of novel therapeutic strategies and enhance our comprehension of mitochondrial function and its broader implications in health and disease.
